MilliporeSigma Announces MoU with SKKU Institute of Quantum Biophysics for In-depth Scientific Collaboration
News Release
- The signing of MoU marks steps towards the first industry-academia collaboration for the Life Science business in quantum biophysics medicines in South Korea
Burlington, MA, December 13, 2021 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the Life Science business signed a non-binding Memorandum of Understanding (MoU) with the Institute of Quantum Biophysics, Sung Kyun Kwan University (SKKU), South Korea, outlining its planned support of the development of diagnostics and therapeutic solutions based on quantum biophysics theory and phenomena.
The signing ceremony, held at Sung Kyun Kwan University in Suwon, was attended by Nam-Koo Lee of the Life Science business and Professors Luke P. Lee and Han-Sang Cho, both of the Institute of Quantum Biophysics, SKKU.
Under this partnership, the Life Science business sector plans to offer seminars and training programs to promote the exchange of knowledge and information, as well as provide scholarship and internship programs to support local talent development in bioscience.
“Quantum biophysics is an up-and-coming research field and is expected to have a significant impact on advancing life science and precision medicine for its ability to create a computer model of predictions within extremely large data sets,” said Stephen Nam-Koo Lee, Head of Research Solutions for Korea & Taiwan, Life Science business sector, Korea. “We are committed to working closely with academia to support the products and services needed for this research.”
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
To continue reading please sign in or create an account.
Don't Have An Account?